Firebrick Pharma (ASX:FRE) is an Australian pharmaceutical developer focused on developing and commercializing novel formulations and uses of povidone-iodine. After more than 10 years of R&D including multiple human clinical trials, Firebrick's first product, Nasodine® Nasal Spray, is now available
View the full Corporate Spotlight
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 7.9¢ | Day High | 7.9¢ | Day Low | 7.2¢ | |||
| Daily Volume | 22431 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 1 | 7.2¢ | 14675 | 2 | 8.0¢ | 47101 | |
| Dr. Peter Molloy | Chief Executive Officer, Founder, Executive Chairman of the Board |
| Mr. Stephen Francis Goodall | Founder, Chief Operating Officer, Executive Director |
| Mr. Kavi Bekarma | Chief Financial Officer |
| Mr. Stephen Buckley | Company Secretary |
| Dr. Phyllis Gardner | Non-Executive Director |
| Mr. Peter Kash | Non-Executive Director |
Data source: Refinitiv
